Return to work for patients in high-risk professions diagnosed with a sudden cardiac death-predisposing genetic heart disease.

Competing Interests: Disclosures M.J.A. is a consultant for Abbott, BioMarin Pharmaceuticals, Boston Scientific, Bristol Myers Squibb, Illumina, Invitae, Medtronic, Solid Biosciences, Tenaya Therapeutics, and UpToDate. Dr Ackerman and Mayo Clinic are involved in an equity/intellectual property/royalty relationship with AliveCor, Anumana, ARMGO Pharma, Pfizer, Prolaio, and Thryv Therapeutics. However, none of these entities have contributed to this study in any manner.